Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02335671 · ClinicalTrials.gov registry record · NA
Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT02335671 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT02335671, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the use of intra-operative Magnetic Resonance Imaging (MRI) and Mass Spectrometry (MS) during breast conserving surgery, and to determine if these tests are capable of accurately predicting the presence or absence of breast tumor in surgical specimens at the margins.
Interventions
- PROCEDURE Intra-operative Magnetic Resonance Imaging (MRI)
- OTHER Mass Spectrometer Analysis of Tissue Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-02 |
| Est. Completion | 2023-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02335671
The ClinicalTrials.gov registry entry for NCT02335671 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intra-operative Magnetic Resonance Imaging (MRI) is the first listed.
NCT02335671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02335671 about?
NCT02335671 is a clinical study titled "Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy". The purpose of this study is to investigate the use of intra-operative Magnetic Resonance Imaging (MRI) and Mass Spectrometry (MS) during breast conserving surgery, and to determine if these tests are capable of accurately predicting the presence or absence of breast tumor in surgical specimens at t...
What is the current status of trial NCT02335671?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2015-02. Estimated completion is 2023-01.
What interventions are being tested in trial NCT02335671?
The interventions under investigation include: Intra-operative Magnetic Resonance Imaging (MRI) (PROCEDURE), Mass Spectrometer Analysis of Tissue Sample (OTHER).
Who is sponsoring clinical trial NCT02335671?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.